Abstract
COVID-19 has led to more than 5 million deaths to date.[1] COVID-19 presentation can range from a simple asymptomatic viral infection to acute respiratory distress syndrome (ARDS)[2]; 15 to 20% of patients develop severe pneumonia and experience coagulopathy disorders. Severe COVID-19 occurs in the context of hyperinflammation that could potentially generate autoimmune disease.[3] We and others have shown the presence of antiphospholipid (aPL) autoantibodies in patients with COVID-19.[4] However, there remains contention if these aPLs represent transient antibodies associated with infection, or “true” aPL reflective of potential autoimmune-associated coagulopathy, namely, antiphospholipid syndrome (APS).[5] [6] Thus, only if they can be shown to persist for at least 12 weeks, can they be considered essential markers for the diagnosis of APS.[7] [8]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.